View Past PerformanceBiocure Technology バランスシートの健全性財務の健全性 基準チェック /46Biocure Technologyの総株主資本はCA$1.3M 、総負債はCA$51.7Kで、負債比率は3.9%となります。総資産と総負債はそれぞれCA$2.0MとCA$643.8Kです。主要情報3.87%負債資本比率CA$51.71k負債インタレスト・カバレッジ・レシオn/a現金CA$5.67kエクイティCA$1.33m負債合計CA$643.83k総資産CA$1.98m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 28Biocure Technology Inc., Annual General Meeting, Jul 30, 2025Biocure Technology Inc., Annual General Meeting, Jul 30, 2025. Location: british columbia, vancouver Canadaお知らせ • Apr 22Biocure Technology Inc. announced that it expects to receive CAD 0.15 million in fundingBiocure Technology Inc. announced a non-brokered private placement financing of up to 7,500,000 units at CAD 0.02 per Unit of the Company for aggregate proceeds of up to CAD 150,000 on April 21, 2025. Each Unit will consist of one 1 common share in the capital of the Company and one transferrable common share purchase warrant. Each Warrant entitles the holder thereof to purchase one Share at a price of CAD 0.05 for a period of five (5) years from the date of issuance. The issuance of securities in connection with this Offering will be subject to Canadian Securities Exchange (“CSE”) approval and the securities will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable Canadian securities laws.お知らせ • Dec 20Biocure Technology Inc. announced that it expects to receive CAD 0.2 million in fundingBiocure Technology Inc. announced a non-brokered financing to raise 10,000,000 common shares at an issue price of CAD 0.02 per share for the gross proceeds of CAD 200,000 on December 19, 2024. No finders' fees are expected to be paid on any portion of the placement. No new insiders or control persons are expected to be created as a result of the placement. Existing insiders of the company are expected to participate in the placement.お知らせ • Sep 20+ 1 more updateAtriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE).Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE) on September 8, 2023. Pursuant to the Transaction, Biocure Technology Inc. will issue common shares in its capital to the shareholders in the capital of Atriva on the basis of a proposed exchange ratio such that, following the closing of the Transaction, on a fully diluted basis, approximately 75% of the securities of the Resulting Issuer will be held by current Atriva securityholders, together with subscribers in a concurrent financing, and approximately 25% of the securities of the Resulting Issuer will be held by current CURE shareholders. the transaction is subject to the completion of satisfactory due diligence, the parties entering into a definitive agreement with respect to the Transaction on or before November 30, 2023, the completion of a private placement by Atriva or CURE and the approval of the shareholders of the Company and Atriva, and the approval of the CSE and other applicable regulatory authorities.お知らせ • Sep 10Biocure Technology Inc. Announces Chief Executive Officer ChangesBiocure Technology Inc. announced resignation of Sang Mok Lee as chief executive officer. The company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed as CEO. Mr. Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high-net-worth individuals and institutional investors.お知らせ • Sep 09Biocure Technology Inc. Announces Board of Director ChangesBiocure Technology Inc. announced resignation of Sang Mok Lee from the board of directors. The company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed to the board of directors. Mr. Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high-net-worth individuals and institutional investors.お知らせ • Jul 06Biocure Technology Inc. Announces That Berkan Unal Has Resigned from Its Board of DirectorsBiocure Technology Inc. announced that Berkan Unal has resigned from its board of directors. The Company will be seeking suitable candidates to enhance the composition of the board of directors in the future.お知らせ • Feb 01Biocure Technology Inc. announced that it has received CAD 0.2376 million in fundingBiocure Technology Inc. announced a non-brokered private placement of 55,000 shares at an issue price of CAD 4.32 per share for gross proceeds of CAD 237,600 on January 30, 2023. The company holds now 92.10% interest in BPK.お知らせ • Jan 18Biocure Technology Inc. announced that it has received CAD 0.0541 million in fundingBiocure Technology Inc. announced a non-brokered private placement of 12,500 shares at an issue price of CAD 4.328 per share for gross proceeds of CAD 54,100 on January 17, 2023. The company holds now 93.42% interest in BPK.財務状況分析短期負債: BICT.Fの 短期資産 ( CA$12.7K ) は 短期負債 ( CA$592.1K ) をカバーしていません。長期負債: BICT.Fの短期資産 ( CA$12.7K ) は 長期負債 ( CA$51.7K ) をカバーしていません。デット・ツー・エクイティの歴史と分析負債レベル: BICT.Fの 純負債対資本比率 ( 3.4% ) は 満足できる 水準であると考えられます。負債の削減: BICT.Fは 5 年前には株主資本がマイナスでしたが、現在はプラスになっており、改善されています。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: 利益は出ていないものの、 BICT.Fは現在のプラスの フリーキャッシュフロー レベルを維持すれば、3 年以上は十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: BICT.Fは利益は出ていませんが、フリーキャッシュフローがプラスであり、年間40.5 % 増加しているため、3 年以上は十分なキャッシュランウェイがあります。健全な企業の発掘7D1Y7D1Y7D1YMaterials 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/10 08:01終値2025/05/14 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biocure Technology Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 28Biocure Technology Inc., Annual General Meeting, Jul 30, 2025Biocure Technology Inc., Annual General Meeting, Jul 30, 2025. Location: british columbia, vancouver Canada
お知らせ • Apr 22Biocure Technology Inc. announced that it expects to receive CAD 0.15 million in fundingBiocure Technology Inc. announced a non-brokered private placement financing of up to 7,500,000 units at CAD 0.02 per Unit of the Company for aggregate proceeds of up to CAD 150,000 on April 21, 2025. Each Unit will consist of one 1 common share in the capital of the Company and one transferrable common share purchase warrant. Each Warrant entitles the holder thereof to purchase one Share at a price of CAD 0.05 for a period of five (5) years from the date of issuance. The issuance of securities in connection with this Offering will be subject to Canadian Securities Exchange (“CSE”) approval and the securities will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable Canadian securities laws.
お知らせ • Dec 20Biocure Technology Inc. announced that it expects to receive CAD 0.2 million in fundingBiocure Technology Inc. announced a non-brokered financing to raise 10,000,000 common shares at an issue price of CAD 0.02 per share for the gross proceeds of CAD 200,000 on December 19, 2024. No finders' fees are expected to be paid on any portion of the placement. No new insiders or control persons are expected to be created as a result of the placement. Existing insiders of the company are expected to participate in the placement.
お知らせ • Sep 20+ 1 more updateAtriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE).Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE) on September 8, 2023. Pursuant to the Transaction, Biocure Technology Inc. will issue common shares in its capital to the shareholders in the capital of Atriva on the basis of a proposed exchange ratio such that, following the closing of the Transaction, on a fully diluted basis, approximately 75% of the securities of the Resulting Issuer will be held by current Atriva securityholders, together with subscribers in a concurrent financing, and approximately 25% of the securities of the Resulting Issuer will be held by current CURE shareholders. the transaction is subject to the completion of satisfactory due diligence, the parties entering into a definitive agreement with respect to the Transaction on or before November 30, 2023, the completion of a private placement by Atriva or CURE and the approval of the shareholders of the Company and Atriva, and the approval of the CSE and other applicable regulatory authorities.
お知らせ • Sep 10Biocure Technology Inc. Announces Chief Executive Officer ChangesBiocure Technology Inc. announced resignation of Sang Mok Lee as chief executive officer. The company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed as CEO. Mr. Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high-net-worth individuals and institutional investors.
お知らせ • Sep 09Biocure Technology Inc. Announces Board of Director ChangesBiocure Technology Inc. announced resignation of Sang Mok Lee from the board of directors. The company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed to the board of directors. Mr. Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high-net-worth individuals and institutional investors.
お知らせ • Jul 06Biocure Technology Inc. Announces That Berkan Unal Has Resigned from Its Board of DirectorsBiocure Technology Inc. announced that Berkan Unal has resigned from its board of directors. The Company will be seeking suitable candidates to enhance the composition of the board of directors in the future.
お知らせ • Feb 01Biocure Technology Inc. announced that it has received CAD 0.2376 million in fundingBiocure Technology Inc. announced a non-brokered private placement of 55,000 shares at an issue price of CAD 4.32 per share for gross proceeds of CAD 237,600 on January 30, 2023. The company holds now 92.10% interest in BPK.
お知らせ • Jan 18Biocure Technology Inc. announced that it has received CAD 0.0541 million in fundingBiocure Technology Inc. announced a non-brokered private placement of 12,500 shares at an issue price of CAD 4.328 per share for gross proceeds of CAD 54,100 on January 17, 2023. The company holds now 93.42% interest in BPK.